Skip to main content

Peer Review reports

From: Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma

Original Submission
7 Apr 2023 Submitted Original manuscript
24 Aug 2023 Reviewed Reviewer Report
15 Sep 2023 Reviewed Reviewer Report
20 Oct 2023 Author responded Author comments - Hongchao Li
Resubmission - Version 2
20 Oct 2023 Submitted Manuscript version 2
31 Oct 2023 Author responded Author comments - Hongchao Li
Resubmission - Version 3
31 Oct 2023 Submitted Manuscript version 3
4 Nov 2023 Author responded Author comments - Hongchao Li
Resubmission - Version 4
4 Nov 2023 Submitted Manuscript version 4
11 Nov 2023 Author responded Author comments - Hongchao Li
Resubmission - Version 5
11 Nov 2023 Submitted Manuscript version 5
13 Nov 2023 Author responded Author comments - Hongchao Li
Resubmission - Version 6
13 Nov 2023 Submitted Manuscript version 6
28 Nov 2023 Reviewed Reviewer Report
15 Jan 2024 Reviewed Reviewer Report
Resubmission - Version 7
Submitted Manuscript version 7
Publishing
23 May 2024 Editorially accepted
29 May 2024 Article published 10.1186/s12913-024-11142-5

You can find further information about peer review here.

Back to article page